Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL) from its SEC filings: 2022 revenue $125,000 (+0% vs the year before), net margin -15035%, free cash flow -$32.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2022) | $125,000 |
| Revenue growth | +0% |
| Net income | -$18.8 million |
| Net margin | -15035.2% |
| Free cash flow | -$32.7 million |
| Diluted EPS | $-0.65 |
| Latest quarter (Q3 2022 (calendar)) revenue vs a year earlier | +0% |
| Cash | $201.6 million |
| Long-term debt | $1.7 million |
| Share count, 1 year | +39% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.